CompanyTNGXNasdaqBoston, MA

Tango Therapeutics, Inc.

Tango Therapeutics discovers and develops precision medicine cancer therapies based on synthetic lethality.

SEC EDGAR ClinicalTrials.gov tangotx.com

SCHEDULE 13G/AAug 14Latest SEC filing

Aug 11Latest story

August 2026

Tango reports Phase 1/2 pancreatic cancer data, eyes Phase 3 as it posts Q2 2026 results

Aug 11Quarterly updateTango Therapeutics, Inc.

Tango Therapeutics files new $400 million at-the-market equity offering with Leerink Partners

Aug 11FinancingTango Therapeutics, Inc.

Tango Therapeutics' Executive Chair Barbara Weber departs, separation agreement filed

Aug 7PeopleTango Therapeutics, Inc.